BRPI0112411B8 - uso de isolados de vírus parapox inativado - Google Patents

uso de isolados de vírus parapox inativado

Info

Publication number
BRPI0112411B8
BRPI0112411B8 BRPI0112411A BRPI0112411B8 BR PI0112411 B8 BRPI0112411 B8 BR PI0112411B8 BR PI0112411 A BRPI0112411 A BR PI0112411A BR PI0112411 B8 BRPI0112411 B8 BR PI0112411B8
Authority
BR
Brazil
Prior art keywords
virus isolates
orf
strains
medicament
parapox virus
Prior art date
Application number
Other languages
English (en)
Inventor
Knorr Andreas
Siegling Angela
Hirth-Dietrich Claudia
Theiss Gudrun
Weber Olaf
Schlapp Tobias
Original Assignee
Aicuris Gmbh & Co Kg
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg, Bayer Ag filed Critical Aicuris Gmbh & Co Kg
Priority claimed from PCT/EP2001/007978 external-priority patent/WO2002004019A2/de
Publication of BR0112411A publication Critical patent/BR0112411A/pt
Publication of BRPI0112411B1 publication Critical patent/BRPI0112411B1/pt
Publication of BRPI0112411B8 publication Critical patent/BRPI0112411B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24261—Methods of inactivation or attenuation
    • C12N2710/24264—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"aplicação de cepas do vírus parapox ovis contra fibroses de órgãos". a presente invenção refere-se ao emprego humano de vírus parapox inativados na profilaxia e tratamento de doenças que ocorrem junto com maior deposição de colágeno, sendo que podem ser atingidos tanto órgãos internos, tais como por exemplo, o fígado, como também a pele e seus campos anexos. são atingidos especialmente fibrose hepática ou cirrose hepática em conseqüência da hepatite por vírus ou doenças hepáticas induzidas pelo etanol.
BRPI0112411-0 2000-07-11 2001-07-11 uso de isolados de vírus parapox inativado BRPI0112411B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10033581.0 2000-07-11
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
DE10122233.5 2001-05-08
PCT/EP2001/007978 WO2002004019A2 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen

Publications (3)

Publication Number Publication Date
BR0112411A BR0112411A (pt) 2003-05-27
BRPI0112411B1 BRPI0112411B1 (pt) 2018-02-27
BRPI0112411B8 true BRPI0112411B8 (pt) 2021-05-25

Family

ID=7648485

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0112411-0 BRPI0112411B8 (pt) 2000-07-11 2001-07-11 uso de isolados de vírus parapox inativado

Country Status (14)

Country Link
JP (2) JP5587950B2 (pt)
KR (1) KR100845643B1 (pt)
CN (1) CN101444539B (pt)
AT (1) ATE445413T1 (pt)
BR (1) BRPI0112411B8 (pt)
DE (2) DE10122233A1 (pt)
DK (1) DK1303302T3 (pt)
DO (1) DOP2001000210A (pt)
EC (1) ECSP034420A (pt)
ES (1) ES2332355T3 (pt)
PE (1) PE20020218A1 (pt)
PT (1) PT1303302E (pt)
SV (1) SV2002000527A (pt)
ZA (1) ZA200300276B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
WO2017141942A1 (ja) * 2016-02-16 2017-08-24 国立大学法人大阪大学 線維化を治療するための医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2125846T3 (es) * 1996-04-15 2001-12-16 Anton Prof Dr Med Vet Dr Mayr Nuevas indicaciones para el empleo de inductores de parainmunidad multipotentes a partir de virus de viruela o virus de paraviruela atenuados, no inmunogenos, como medicamento.

Also Published As

Publication number Publication date
PT1303302E (pt) 2009-11-11
DE50115181D1 (de) 2009-11-26
JP2012214492A (ja) 2012-11-08
DK1303302T3 (da) 2010-02-08
DE10122233A1 (de) 2002-01-24
ATE445413T1 (de) 2009-10-15
KR20030019562A (ko) 2003-03-06
CN101444539B (zh) 2016-07-06
PE20020218A1 (es) 2002-05-19
ES2332355T3 (es) 2010-02-03
JP5587950B2 (ja) 2014-09-10
ZA200300276B (en) 2004-04-13
JP5950964B2 (ja) 2016-07-13
BR0112411A (pt) 2003-05-27
KR100845643B1 (ko) 2008-07-10
CN101444539A (zh) 2009-06-03
DOP2001000210A (es) 2002-12-15
SV2002000527A (es) 2002-10-24
BRPI0112411B1 (pt) 2018-02-27
ECSP034420A (es) 2003-03-10
JP2014196329A (ja) 2014-10-16

Similar Documents

Publication Publication Date Title
NO312225B2 (no) Farmasoytiske preparater av fluoxetin
CY1105127T1 (el) Συνθεση για την προληψη καρδιαγγειακων νοσων
BR0112962A (pt) Composições farmacêuticas para o tratamento de condições inflamatórias e ulcerativas dolorosas de maioria das superfìcies epiteliais tais como mucosite, estomatite e sìndrome de behcet
CA2130360A1 (en) Sulfonic Acid Derivatives in the Treatment of Viral Diseases
ES2058418T3 (es) Preparacion farmaceutica contra enfermedades viricas que comprende un extracto de higado.
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
ATE374208T1 (de) Pharmakologisch aktive antivirale peptide und methoden zu ihrer anwendung
PT1303302E (pt) Utilização de estirpes de parapoxvirus ovis contra fibroses de órgãos
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
NO20013605D0 (no) Preparat for vorter
NO20052960L (no) Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi
ES2185310T3 (es) Agente antivirico herbario.
WO2002004019A3 (de) Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen
TR200200724T2 (tr) Cilde sürülebilen farmasötik bileşimlerin antimikrobik etkisinin arttırılması için yağlı asit/amino asit sabunlarının kullanımı
Konlee Sulfated polysaccharides (chondroitin sulfate and carrageenan) plus glucosamine sulfate are potent inhibitors of HIV
ATE236195T1 (de) Entgiftung von pharmazeutischen wirkstoffen durch cyclodextrin-oligomere
Hecht A new focus on primary HIV infection
DE69130571D1 (de) Peptide, die infektionen mit menschlichem immunschwächevirus hemmen und deren anwendungsweisen
Kissinger Geneva conference points out problems
Ishak et al. A13 Oral infection of Aedes aegypti and Aedes albopictus with Dengue-1 viruses: Susceptibility comparison and molecular analysis
Santiago Large HIV vaccine trial begins
BR0112407A (pt) Uso de cepas de parapoxvìrus ovis para produzir medicamentos antivirais e medicamentos contra câncer
Mishriki The case of the creeping papules
AP2001002323A0 (en) The use of aqueous herbal preparation, pmz10, as an alternative remedy in the treatment of HIV/AIDS.
SHINONAGA et al. Two new species of the tribe Hydrotaeini from Indonesia (Diptera: Muscidae)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT

B25G Requested change of headquarter approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070107873/RJ DE 03/08/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24, 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2678 DE 03-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.